Video

Urology Times 50 Innovations Series: LHRH analogues in prostate cancer

Author(s):

Urology Times staff

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

Current Time 0:00
Duration 9:43
Loaded: 0%
Stream Type LIVE
Remaining Time 9:43
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.

    Related Videos
    Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
    Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
    Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
    Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
    Dr Louise Kostos answers a question during a Zoom video interview
    An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
    Rana McKay, MD, on the role of radium-223 in the modern era
    Rana McKay, MD, on the role of radium-223 in the modern era
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos discusses PSA kinetics in mHSPC
    Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
    The importance of PSADT in high-risk, biochemically recurrent prostate cancer
    Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
    Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
    Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
    Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
    Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
    Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
    Related Content
    Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
    April 3rd 2025

    CD46-targeting ADC shows encouraging clinical activity in mCPRC

    Hannah Clarke
    The company plans to initiate the phase 2 monotherapy trial by mid-year.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    FDA updates in urology: March 2025
    April 1st 2025

    FDA updates in urology: March 2025

    Hannah Clarke
    A recap of the FDA submissions and regulatory decisions in urology from March 2025.
    Dr. Schwen on focal therapies for prostate cancer
    January 11th 2024

    Dr. Schwen on focal therapies for prostate cancer

    Cleveland Clinic
    Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
    NeuroSAFE procedure for RARP leads to improved erectile function
    March 27th 2025

    NeuroSAFE procedure for RARP leads to improved erectile function

    Hannah Clarke
    “Our results show that by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery,” says Professor Greg L. Shaw.
    Data reinforce isodose MHFRT as standard of care radiotherapy regimen
    March 22nd 2025

    Data reinforce isodose MHFRT as standard of care radiotherapy regimen

    Hannah Clarke
    “These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
    © 2025 MJH Life Sciences

    All rights reserved.